MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-13-2026
Capricor Therapeutics ROE Ratio 2011-2026 | CAPR
Annual ROE Ratio Capricor Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -34.35 | -27.82 | -98.61 | -246.22 | -63.83 | -48.43 | -111.73 | -329.13 | 21.66 | 469.8 | 1246.14 | 99.49 | 1662.41 | 1131.43 | -588.02 | -59.01 | -16.34 | -249.79 | -113.43 | -63.79 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1662.41 | -588.02 | 129.02 |
Quarterly ROE Ratio Capricor Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -85.27 | -91.48 | -157.82 | -186.26 | -167.15 | 190.33 | -61.0 | -90.53 | -37.41 | -78.71 | -474.15 | -236.15 | -110.99 | -121.69 | -94.61 | -70.81 | -39.09 | -52.95 | -54.61 | -47.78 | -33.61 | -57.1 | -73.16 | -97.64 | -90.25 | -179.86 | -245.71 | -295.33 | -258.5 | -282.86 | -224.17 | -167.49 | -87.95 | 45.28 | 186.77 | 324.27 | 356.93 | 639.16 | 808.63 | 1028.41 | 921.83 | 946.54 | 688.86 | 405.54 | 68.63 | 357.52 | 636.54 | 2274.4 | 2255.03 | 3386.46 | 4229.01 | 5056.71 | 3394.3 | 2806.29 | 1086.84 | -632.61 | -1764.05 | -588.02 | -588.02 | -588.02 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5056.71 | -1764.05 | 393.02 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-528.29 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-32.54 | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
21.0 | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-380.03 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
30.52 | - | 0.74 % | $ 768 M |  Israel |
 |
Galera Therapeutics
GRTX
|
3750.6 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-55.98 | - | -18.52 % | $ 27.3 M | Britain |
 |
Esperion Therapeutics
ESPR
|
7.51 | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-17.59 | $ 32.59 | -6.89 % | $ 877 M | USA |
|
Forte Biosciences
FBRX
|
-113.75 | $ 21.59 | -1.86 % | $ 280 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.4 | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-948.23 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-69.02 | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
-152.74 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
575.45 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
BioNTech SE
BNTX
|
-5.91 | $ 92.14 | 1.33 % | $ 22.3 B | Germany |
 |
Grifols, S.A.
GRFS
|
2.47 | $ 7.98 | -1.6 % | $ 5.42 B |  Spain |
 |
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.7 | 3.03 % | $ 452 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
Heron Therapeutics
HRTX
|
-139.54 | $ 0.86 | -1.42 % | $ 143 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
43.82 | - | -4.36 % | $ 27 M | USA |
 |
Compugen Ltd.
CGEN
|
34.4 | $ 2.8 | 7.28 % | $ 262 M | Israel |
 |
Anika Therapeutics
ANIK
|
-7.58 | $ 14.88 | -0.93 % | $ 213 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Incyte Corporation
INCY
|
24.9 | $ 97.16 | -0.26 % | $ 19 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
-46.9 | $ 75.56 | -0.29 % | $ 12.1 B | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 3.4 | -1.16 % | $ 5.6 M | Israel |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Coherus BioSciences
CHRS
|
275.39 | $ 1.61 | 2.55 % | $ 189 M | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-146.95 | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 20.86 | -0.71 % | $ 2.65 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |